In­cyte inks $750M deal for im­mune and neu­ro biotech Escient

Last year
Startups
Deals

Why VC leg­end Bob Nelsen is mak­ing the biggest ini­tial bet of his 37-year ca­reer on Xaira

Last year
People
Startups

FDA ap­proves Im­mu­ni­ty­Bio's blad­der can­cer ther­a­py com­bo

Last year
FDA+

AI drug dis­cov­ery start­up Benev­o­len­tAI cuts 30% of staff, clos­es US of­fice 

Last year
People
AI

Head­space will add more men­tal-health ser­vices to its con­sumer busi­ness, go­ing against trend

Last year
Health Tech

Ex­clu­sive: In $1B+ bet on AI, bio­phar­ma heavy­weights back new start­up to up­end drug R&D

Last year
Startups
Deals

Sanofi’s BTK in­hibitor from Prin­cip­ia deal suc­ceeds in Phase 3 im­mune throm­bo­cy­tope­nia tri­al

Last year
R&D

FDA hands CRL to Abeon­a's rare skin dis­ease cell ther­a­py

Last year
FDA+
Manufacturing

No­var­tis will change CRO re­la­tion­ships ‘over time’ as Sen­ate bill tar­get­ing Chi­nese com­pa­nies looms

Last year
Pharma

Weeks af­ter clos­ing Bris­tol My­ers deal, Karuna's ex-CEO heads to Black­stone-backed An­thos

Last year
People
Pharma

Re­gen­eron’s $500M fund spot­lights cor­po­rate ven­ture’s in­flu­en­tial role in biotech

Last year
Financing
Startups

Mar­ket­ing pay­ments to can­cer doc­tors lead to more pre­scrip­tions but not bet­ter out­comes, NBER pa­per finds

Last year
Pharma
Marketing

Ex­clu­sive: Gene edit­ing start­up Seam­less hires ex-Ho­mol­o­gy leader, dou­bles seed round

Last year
People
Startups

Car­di­nal Health los­es Op­tum­Rx con­tract to McKesson

Last year
Pharma

Re­searchers seek FDA trans­paren­cy on use of sur­ro­gate end­points out­side of on­col­o­gy

Last year
FDA+

Bios­plice search­es for a path for­ward af­ter os­teoarthri­tis drug fails late-stage study

Last year
R&D

Ipsen, Sky­hawk ink deal worth up to $1.8B; He­p­i­on to wind down NASH tri­al

Last year
News Briefing

Pfiz­er to shut­ter re­search op­er­a­tions at Col­orado site ac­quired in Ar­ray deal

Last year
People
Pharma

Rube­do pulls in $40M Se­ries A to ad­vance atopic der­mati­tis can­di­date tar­get­ing ag­ing cells

Last year
Financing

Bris­tol My­ers, Cel­lares sign glob­al CAR-T deal as bio­phar­ma com­pa­nies look to di­ver­si­fy man­u­fac­tur­ing part­ners 

Last year
Deals
Cell/Gene Tx

Ei­sai, BioArc­tic to de­vel­op new drug for Alzheimer’s that can cross blood-brain bar­ri­er

Last year
Deals
R&D

Boehringer In­gel­heim inks chron­ic liv­er dis­ease re­search pact with Ochre Bio

Last year
Deals
R&D

Irish biotech col­lects $75M in Se­ries B to start Phase 3 rare joint tu­mor tri­al

Last year
Financing

Nvidi­a's biotech mo­ment; Re­gen­eron launch­es ven­ture arm; New GLP-1 play­er en­ters; Sanofi re­jigs can­cer pact, vac­cine ...

Last year
Weekly
First page Previous page 168169170171172173174 Next page Last page
A service from the Financial Times